Nordic Nanovector - Fundamentale forhold 2019 (NANO)

[Kmsteen]

Det kan vel trolig brukes som såkalt off label bruk, også innenfor andre indikasjoner (og da såklart 2.linjebehandling FL). Slik jeg tolker det kan behandlere da også bruke betalutin mot f.eks MZL og MCL. Spesielt MZL vil jo kanskje være aktuelt, om de har nok data til at klinikerne er overbevist.

[OTB]

Hvis vi oppdaterer konkurrent oversikten med litt notater fra tråden her og AlphaHunter3 sine ! antagelser av CR/ORR for Archer 1 så ser konkurranse bildet ser slik ut:

Sammenlign dette med verdien av andre selskap i samme kategori.
14.03.2019 BioCapital Europe

Ser vi tegn på at noen ønsker en bit av denne kaken i dag ?

[TekBot]

Nordic Nanovector ASA: Invitation to R&D Day in Oslo and Webcast

Oslo, Norway, 29 August 2019

Nordic Nanovector ASA (OSE: NANO) announces that it will host a R&D Day in Oslo
…

Vis børsmeldingen

on Tuesday, 17 September 2019 from 9:30am to 12:30pm CEST. The programme will
include presentations from three external experts and by Nordic Nanovector’s
senior management team. An update on the median Duration of Response (mDoR) of
Betalutin® treatment in the LYMRIT 37-01 trial will also be given during the
day.

Venue: Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo

Meeting Room: Auditorium

To register to attend, please e-mail ir@nordicnanovector.com by 13 September
2019.

The R&D Day will be recorded as a webcast and will be available at
www.nordicnanovector.com in the section: Investors & Media.

The presentations will be available at www.nordicnanovector.com in the section:
Investors & Media/Reports and Presentation/2019.

The preliminary programme is as follows;

09.30-09.50 Nordic Nanovector’s pipeline - Strategic insights Eduardo Bravo, CEO

09.50-10.10 Radioimmunotherapy - Preclinical results with Betalutin® and
comparison of alpha and beta emitters Dr Jean-Pierre Pouget*

10.10-10.40 Future vision for R&D at Nordic Nanovector Dr Jostein Dahle, CSO

10:40-10:50 Introduction to clinical sessions Dr Lisa Rojkjaer, CMO

10.50-11.20 Unmet medical needs and therapeutic landscape for recurrent
follicular and marginal zone lymphoma Prof. Pier Luigi Zinzani*

11:20-11:30 Coffee Break

11.30-12:00 Novel biologic combinations with Betalutin® Dr Arne Kolstad*

12.00-12.20 BLA readiness: CMC commercial plans Dr Marco Renoldi, COO

12.20-12.30 Q&A

*The external experts’ speakers are:

· Dr J.P. Pouget, PhD, Radiobiology and targeted radiotherapy group
Montpellier Cancer Research Institute (IRCM), French National Institute of
Health and Medical Research (INSERM).
· Prof. P. L. Zinzani, Professor of Hematology, Institute of Hematology “L. e
A. Seràgnoli”, University of Bologna.
· Dr A. Kolstad MD, PhD, senior consultant in Medical Oncology and Radiation
Therapy, Dept of Oncology Oslo University Hospital, The Norwegian Radium
Hospital.

For further information, please contact:

IR enquiries

Malene Brondberg, VP Investor Relations and Corporate Communications

Cell: +44 7561 431 762

Email: ir@nordicnanovector.com

International Media Enquiries

Mark Swallow/David Dible (Citigate Dewe Rogerson)

Tel: +44 207 638 9571

Email: nordicnanovector@citigatedewerogerson.com

About Nordic Nanovector

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers. Nordic Nanovector’s lead clinical-stage candidate is
Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to
advance the treatment of non-Hodgkin’s lymphoma (NHL). NHL is an indication with
substantial unmet medical need, representing a growing market forecast to be
worth nearly USD 29 billion by 2026. Nordic Nanovector intends to retain
marketing rights and to actively participate in the commercialisation of
Betalutin® in core markets. Further information can be found at
www.nordicnanovector.com

Forward-looking statements

This press release contains certain forward-looking statements. These
statements are based on management’s current expectations and are subject to
uncertainty and changes in circumstances, since they relate to events and depend
on circumstances that will occur in the future and which, by their nature, will
have an impact on Nordic Nanovector’s business, financial condition and results
of operations. The terms “anticipates”, “assumes”, “believes”, “can”, “could”,
“estimates”, “expects”, “forecasts”, “intends”, “may”, “might”, “plans”,
“should”, “projects”, “targets”, “will”, “would” or, in each case, their
negative, or other variations or comparable terminology are used to identify
forward-looking statements. These forward-looking statements are not historic
facts. There are a number of factors that could cause actual results and
developments to differ materially from those expressed or implied in the forward
-looking statements. Factors that could cause these differences include, but are
not limited to, risks associated with implementation of Nordic Nanovector’s
strategy, risks and uncertainties associated with the development and/or
approval of Nordic Nanovector’s product candidates, ongoing and future clinical
trials and expected trial results, the ability to commercialise Betalutin®,
technology changes and new products in Nordic Nanovector’s potential market and
industry, Nordic Nanovector’s freedom to operate (competitors patents) in
respect of the products it develops, the ability to develop new products and
enhance existing products, the impact of competition, changes in general economy
and industry conditions, and legislative, regulatory and political factors. No
assurance can be given that such expectations will prove to have been correct.
Nordic Nanovector disclaims any obligation to update or revise any forward
-looking statements, whether as a result of new information, future events or
otherwise. This information is subject to a duty of disclosure pursuant to
Section 5-12 of the Securities Trading Act.

Kilde

[Syklisten]

Da kom katta ut av sekken. Programmet er svært interessant, men bærer også preg av at markedet har manglet adekvat informasjon om den siste tids utvikling og at de med dette håper å bøte på det. Tror dette var bakgrunnen for gårsdagens snu operasjon.

[amagad]

Blir bra å høre fra både Kolstad og Zinzani igjen

[pdx]

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

1. @Savepig (495 likes)

Nordic Nanovector - Småprat 2019 (NANO)

Wow, skal si folk er nedkjørt og deprimerte og tolker ting skikkelig negativt her.

2. @InVivo (472 likes)

http://www.nordicnanovector.com/investors-and-media/press-releases?page=/en/pressreleases/nordic-nanovector-presentations-at-the-society-of-nuclear-medicine-%26-molecular-imaging-%28snmmi%29-2019-annual-meeting-1699869

3. @Nocturne (424 likes)

Nordic Nanovector - Teknisk analyse (NANO) (TA)

Kjenner litt prestasjonsangst her nå @tony

Resten av topp 10:

4. @anon21766851 (319 likes)

5. @Merlin (239 likes)

6. @vegar_beider (230 likes)

7. @Teejay (194 likes)

8. @TyrionIV (173 likes)

9. @larsmkn (152 likes)

10. @Fornybar (147 likes)

Gratulerer!

[TekBot]

Nordic Nanovector to participate in three upcoming investor conferences in the US

Oslo, Norway, 4 September 2019

Nordic Nanovector ASA (OSE: NANO) announces that its CEO, Eduardo Bravo, will
…

Vis børsmeldingen

participate and present at the following upcoming investor conferences during
September:

· Citi 14th Annual Biotech Conference in Boston on 4-5 September
· BioCentury 26th Annual NewsMakers in the Biotech Industry 2019 in New York
on 6 September
· HC Wainwright & Co. 21st Global Investment Conference in New York on 9-10
September

The company presentation will be available on the 5 September on the investors
and media page.

For further information, please contact:

IR enquiries

Malene Brondberg, VP Investor Relations and Corporate Communications

Cell: +44 7561 431 762

Email: ir@nordicnanovector.com

Media Enquiries

Mark Swallow/David Dible (Citigate Dewe Rogerson)

Tel: +44 207 638 9571

Email: nordicnanovector@citigatedewerogerson.com

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers.

Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37
-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin’s
lymphoma (NHL). NHL is an indication with substantial unmet medical need,
representing a growing market forecast to be worth nearly USD 29 billion by
2026. Nordic Nanovector intends to retain marketing rights and to actively
participate in the commercialisation of Betalutin® in core markets.

Further information can be found at www.nordicnanovector.com.

Forward-looking statements

This press release contains certain forward-looking statements. These
statements are based on management’s current expectations and are subject to
uncertainty and changes in circumstances, since they relate to events and depend
on circumstances that will occur in the future and which, by their nature, will
have an impact on Nordic Nanovector’s business, financial condition and results
of operations. The terms “anticipates”, “assumes”, “believes”, “can”, “could”,
“estimates”, “expects”, “forecasts”, “intends”, “may”, “might”, “plans”,
“should”, “projects”, “targets”, “will”, “would” or, in each case, their
negative, or other variations or comparable terminology are used to identify
forward-looking statements. These forward-looking statements are not historic
facts. There are a number of factors that could cause actual results and
developments to differ materially from those expressed or implied in the forward
-looking statements. Factors that could cause these differences include, but are
not limited to, risks associated with implementation of Nordic Nanovector’s
strategy, risks and uncertainties associated with the development and/or
approval of Nordic Nanovector’s product candidates, ongoing and future clinical
trials and expected trial results, the ability to commercialise Betalutin®,
technology changes and new products in Nordic Nanovector’s potential market and
industry, Nordic Nanovector’s freedom to operate (competitors patents) in
respect of the products it develops, the ability to develop new products and
enhance existing products, the impact of competition, changes in general economy
and industry conditions, and legislative, regulatory and political factors. No
assurance can be given that such expectations will prove to have been correct.
Nordic Nanovector disclaims any obligation to update or revise any forward
-looking statements, whether as a result of new information, future events or
otherwise.

This information is subject to a duty of disclosure pursuant to Sections 4-2 and
5-12 of the Securities Trading Act.

Kilde

[InVivo]

Hm, bygger opp forventinger og oppmerksomhetrundt R&D-dagen, liker det!

[Markusf]

Hele tre investorpresentasjoner. Det er virkelig bra.

I kontekst av denne informasjon tror jeg sannsynligheten for en emisjon i en ikke altfor fjern fremtid øker. Vil anta at de leter etter investorer som er villige til å bidra med $$$, slik at Betalutin pipelinen(e) sikres i overskuelig fremtid

[Hallakis]

Sikkert ikke helt tilfeldig at alle finner sted i US også

[Kukleklu]

Oppdatert 02 september. Noen som ser hva som er oppdatert?

Study of Copanlisib in Combination With Standard Immunochemotherapy in...

[Dunkel]

Mulig dette er forskjellen fra forrige oppdatering. Ser at noen siter har blitt tatt bort og noen andre rekruterer .

https://clinicaltrials.gov/ct2/history/NCT02626455?B=47&A=48&C=Side-by-Side#StudyPageTop

[Hallakis]

Har de alltid hatt primary completion date 30.sept 2021? Isåfall, hvorfor har enkelte vært bekymret for at de kommer før nano i mål?

[Dunkel]

I Januar 2016 , så har dem Primary completion date Mars 2021. Den er nå datert 30.Sept 2021. I parantes så står det , Anticipated…

[Hallakis]

Så Bayer er også 6 mnd forsinket? Og sånn sett burde kursen gå som f på mandag, men det skjer jo ikke

[Salamis]

Fremover blir det nok endel mer søvn på endel flere nanoister, inkludert undertegnede.

[F-Tosca]

Har vel vært litt skremming på gang. Nervøse småsparere med svette hender ser ut til å ha vært et lett bytte.
Men så viser det seg at det er to forsinkede båter, og ikke bare en.
Takk for info om Bayers forsinkelse, @Dunkel og @Kukleklu

[hybrid]

har bayer børsmeldt dette eller nevnt det i andre sammenhenger?

edit: har vel gjerne ikke behov for å melde slikt, sett at bayer har rimelig bredt virksomhetsområde

[Dunkel]

Det vet jeg ikke …

[TheObserver]

Noen som vet om det er forsinkelser i Chronos-3 v Bayer også?